Turquoise-ii: regimens of abt-450/r/ombitasvir and dasabuvir with ribavirin achieve high svr12 rates in hcv genotype 1-infected patients with cirrhosis, regardless of baseline characteristics

Reported by Jules Levin

AASLD Nov 9 2014 Boston

Michael W. Fried, Xavier Forns, Nancy Reau, Heiner Wedemeyer, Mitchell L. Shiffman, Angeles Castro, David Mutimer, Sam Lee, Roger Trinh, Sandra Lovell, Leticia Canizaro, Marcos Pedrosa, Fred Poordad, Thomas Berg